InMed Pharmaceuticals Inc.(INM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.9M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
INM Stock Analysis & AI Quality Score
AI stock analysis and institutional research for InMed Pharmaceuticals Inc. (INM), a Healthcare sector company. INM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.9m in revenue. Based on the latest XBRL financial filings (Q3 2026), InMed Pharmaceuticals Inc. reports net income of $-3.0M, free cash flow of $-1.7M. Top institutional holders of INM by reported 13-F value include SABBY MANAGEMENT,, CITADEL ADVISORS, TWO SIGMA SECURITIES,, based on the most recent SEC filings. INM trades on the Nasdaq exchange and files with the SEC under CIK 1728328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InMed Pharmaceuticals Inc. directly from SEC EDGAR.
Net Income
Q3 2026
$-3.0M
Free Cash Flow
Q3 2026
$-1.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+322.0% YoYNet Income
+58.7% YoYOperating Income
EPS (Diluted)
-21.4% YoYTotal Assets
-7.5% YoYOp. Cash Flow
+55.2% YoY| Metric | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|
| Revenue | $4.6M +322.0% | $1.1M -42.8% | $1.9M |
| Net Income | $-7.7M +58.7% | $-18.6M -82.3% | $-10.2M |
| Operating Income | — | $-18.6M -82.3% | $-10.2M |
| EPS (Diluted) | $-20.14 -21.4% | $-16.59 +12.6% | $-18.98 |
| Total Assets | $11.8M -7.5% | $12.8M +30.7% | $9.8M |
| Operating Cash Flow | $-7.0M +55.2% | $-15.6M -59.2% | $-9.8M |
AI Insight: INM Financial Trends
InMed shows flat $1M quarterly revenue through 2025 but persistent $2-3M losses are eroding equity from $13M to $7M.
• Revenue remained flat at $1M per quarter from Q3 2024 through Q4 2025.
• Net losses consistent at $2M per quarter through most periods, widening to $3M in Q4 2024 and Q1 2026.
• Equity declined from $13M in Q2 2025 to $7M in Q1 2026.
⚠ Revenue disappeared in Q1 2026 after seven quarters of steady $1M.
⚠ Operating cash flow losses of $2M per quarter continue draining balance sheet.
AI Insight: INM Ratio Trends
InMed shows deeply negative profitability metrics with ROE deteriorating to -172.2% in Q1 2026 from -59.6% in Q3 2025.
• Operating margin remained severely negative, ranging from -132.7% in Q3 2024 to -168.1% in Q1 2025.
• ROE volatility persisted with swings from -53.2% in Q2 2025 to -172.2% in Q1 2026.
• ROA showed improvement from -91.4% in Q1 2025 to -45.9% in Q2 2025 before deteriorating again.
⚠ Sharp ROE deterioration to -172.2% in Q1 2026 after relative stabilization in mid-2025.
⚠ Persistent triple-digit negative operating margins indicate ongoing operational challenges requiring monitoring.
Get alerted when INM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for InMed Pharmaceuticals Inc. including:
Top Institutional Holders of INM
SABBY MANAGEMENT, LLC
$142.0K220,260 shCITADEL ADVISORS LLC
$30.3K46,973 shTWO SIGMA SECURITIES, LLC
$12.1K18,718 shUBS Group AG
$5.2K8,068 shPrivate Wealth Management Group, LLC
$3.2K5,000 shSBI Securities Co., Ltd.
$193.00300 shVirtu Financial LLC
$13.0019,980 shFederation des caisses Desjardins du Quebec
$2.002 shBanque Cantonale Vaudoise
$0.006 sh
| Fund | Value | Shares |
|---|---|---|
| SABBY MANAGEMENT, LLC | $142.0K | 220,260 |
| CITADEL ADVISORS LLC | $30.3K | 46,973 |
| TWO SIGMA SECURITIES, LLC | $12.1K | 18,718 |
| UBS Group AG | $5.2K | 8,068 |
| Private Wealth Management Group, LLC | $3.2K | 5,000 |
| SBI Securities Co., Ltd. | $193.00 | 300 |
| Virtu Financial LLC | $13.00 | 19,980 |
| Federation des caisses Desjardins du Quebec | $2.00 | 2 |
| Banque Cantonale Vaudoise | $0.00 | 6 |
More Healthcare Companies
View all Healthcare →Put INM on your watchlist
Track score changes the day InMed Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INM a good stock to buy?
13F Pro's AI-powered analysis of InMed Pharmaceuticals Inc. (INM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INM are available on the INM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of InMed Pharmaceuticals Inc.'s investment landscape.